Table 2.
change from baseline to last follow-up in asthma patients with or without ECRS
| all patients, n = 27 | ECRS (+) group, n = 16 | ECRS (−) group, n = 11 | between two groups | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| baseline | last follow-up | p valuea | at baseline | at last follow-up | p valuea | at baseline | at last follow-up | p valuea | p value‡ | |
| blood eosinophil count(/mm3) | 873 (1851) | 71 (64) | < 0.0001 | 1219 (2353) | 89 (74) | 0.0004 | 338 (364) | 44 (31) | 0.005 | 0.0049 |
| serum IgE (IU/ml) | 485 (713) | 305 (583) | 0.016 | 440 (415) | 261 (263) | 0.0052 | 505 (992) | 367 (873) | 0.95 | 0.15b |
| FeNO (ppb) | 62 (57) | 44 (33) | 0.056 | 84 (62) | 53 (37) | 0.021 | 32 (24) | 32 (24) | 0.53 | 0.007b |
| —Δ%FeNO (%), (range) | 0.7 (69.2), (−68—180) | −19 (57), (−68—157) | 30 (77), (−53—180) | 0.023 | ||||||
| ACT (pts) | 15.2 (5.1) | 19.5 (5.2) | 0.0005 | 16.3 (5.5) | 21.7 (4.8) | 0.0023 | 13.6 (4.2) | 16.4 (4.2) | 0.066 | 0.16b |
| —ΔACT (pts), (range) | 5.3 (4.5), (−4—16) | 5.4 (5.4), (−3—16) | 2.7 (4.4), (−4—9) | 0.24 | ||||||
| %FVC (%) | 91.1 (14.8) | 99.2 (17.5) | 0.031 | 94.7 (14.9) | 100.3 (12.9) | 0.14 | 85.1 (13.2) | 97.7 (23.8) | 0.09 | 0.16b |
| %FEV1 (%) | 83.3 (27.6) | 83.9 (24.2) | 0.62 | 77.4 (24.5) | 79.0 (19.9) | 0.36 | 92.1 (30.7) | 91.5 (29.3) | 0.44 | 0.35b |
| FEV1 / FVC (%) | 71.1 (13.3) | 68.9 (12.9) | 0.32 | 66.6 (12.8) | 65.2 (12.5) | 0.78 | 77.8 (11.6) | 74.6 (11.8) | 0.11 | 0.026b |
| %PEF (%) | 86.2 (28.2) | 89.4 (23.6) | 0.011 | 82.3 (30.8) | 85.3 (24.0) | 0.011 | 92.1 (24.1) | 95.9 (22.7) | 0.53 | 0.29b |
| V50/V25 | 3.5 (1.1) | 3.5 (1.1) | 0.61 | 3.5 (1.2) | 3.1 (0.9) | 0.81 | 3.5 (1.1) | 4.1 (1.1) | 0.26 | 0.78b |
| daily dose of OCS (mg)§, (range) | 8.4 (5.6), (0.5—20) (n = 16) | 5.0 (5.8), (0—20) (n = 16) | 0.0032 | 7.0 (4.8), (0.5—15) (n = 10) | 2.0 (2.4), (0—6) (n = 10) | 0.008 | 10.8 (6.5), (5—20) (n = 6) | 10.0 (6.5), (2.5—20) (n = 6) | 0.16 | 0.29b |
| —ΔOCS (%), (range) | −48.6 (43.3), (−100—0) | −71.3 (37.0), (−100—0) | −10.7 (20.1), (−50—0) | 0.006 | ||||||
| exacerbation (/year), n | 5.6 (4.9) | 2.9 (3.7) | 0.002 | 5.6 (5.6) | 2.4 (3.3) | 0.01 | 5.5 (3.9) | 3.6 (4.2) | 0.0498 | 0.77b |
| —Δexacerbation (%), (range) | −44.7 (61.4), (−100—125) | − 48.4 (62.6),(− 100—125) | −39.9 (62.6), (− 100—100) | 0.82 | ||||||
ECRS eosinophilic chronic rhinosinusitis, NA not available, ACT Asthma Control Test Δ: change from baseline to the last follow-up Data presented as mean (standard deviation), unless otherwise stated. Blood eosinophil counts at last follow-up were examined at 3 months(median, range 1–6). Serum IgE tests at last follow-up were examined at 6 months(median, range 2–6)
FeNO tests at last folloow-up were examined at 9 months(median, range 1–12). Asthma Control Tests(ACT) score at last follow-up was examined at 6 months(median, range 2–12)
Pulmonary function tests at last follow-up were comducted at 4 months(median, range 2–10)
aWilcoxon signed rank test ‡ Mann-Whitney U test § Oral corticosteroid(OCS) doses are provided as prednisone equivalents (mg). b at baseline